A Phase 1 interventional study of Carfilzomib and Lenalidomide in Multiple Myeloma, sponsored by Amgen. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 26th largest by enrollment, is one of 2 that started in 2015, is one of 17 in phase 1, and was the 54th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 19th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2015, is one of 13 in phase 1, and was the 28th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
Key Inclusion Criteria:
Key Exclusion Criteria:
For relapsed disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Administered orally once daily on days 1-21 of each 28-day cycle.
Also known as: Revlimid®
Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
Number of Participants With Adverse Events (AEs)
Safety and tolerability were evaluated according to the type, incidence, and severity of adverse events. An AE is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following serious criteria: * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event The severity of each AE was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
Time frame: From the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.
Change From Baseline in Hemoglobin Levels
Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Change From Baseline in Platelet Count
Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Change From Baseline in Neutrophil Count
Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Change From Baseline in Bilirubin
Time frame: Baseline and Cycle 2 day 1
Change From Baseline in Creatinine
Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
Time frame: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
Time frame: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
Time frame: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
Overall Response Rate (ORR)
Response was determined by the investigator based on the International Myeloma Working Group Uniform Response Criteria (IMWG URC). ORR was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Responses must have been confirmed in 2 consecutive assessments at any time prior to initiation of any new therapy. Disease assessments included serum protein electrophoresis (SPEP) with immunofixation, urine protein electrophoresis (UPEP; 24-hour assessment) with immunofixation, serum free light chain (SFLC), quantitative immunoglobulins, bone marrow aspirates to determine percent plasma cell involvement, and skeletal imaging for plasmacytoma evaluation.
Time frame: Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
Complete Response Rate (CRR)
Complete Response Rate (CRR) is defined as the percentage of participants who achieved a best overall response of either stringent complete response (sCR) or complete response (CR) in accordance with International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). sCR: As for CR, and absence of clonal plasma cells in bone marrow (BM) CR: Negative serum and urine immunofixation, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in BM, and normal SFLC ratio in participants with measurable disease only by SFLC.
Time frame: Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
Progression-free Survival (PFS)
PFS is defined as the time from the first day of study treatment to the earlier of disease progression or death due to any cause. Disease progression was determined by the investigator according to IMWG-URC. Progressive Disease (PD): Increase of 25% from lowest value in serum M-component (absolute increase ≥ 0.5 g/dL), urine M-component (absolute increase ≥ 200 mg per 24 hours) and/or the difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, and/or any new or increase in size of bone lesions or soft tissue plasmacytomas, or development of hypercalcemia. PFS was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed assessment visit, were lost to follow-up or withdrew consent were censored at the date of last disease assessment.
Time frame: From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
Duration of Response (DOR)
Duration of response (DOR) was calculated for participants who achieved a confirmed PR or better based on Investigator assessment and according to the IMWG URC. Duration of overall response is defined as the time from first documentation of response to disease progression or death due to any cause. DOR was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed disease assessment visit, were lost to follow-up, or withdrew consent were censored at the date of last disease assessment.
Time frame: From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
This study was conducted at 21 centers in the United States. The study had 2 parts: dose-evaluation and dose-expansion.
| Milestone | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Started | 10 | 12 | 34 | 9 | 9 | 33 |
| Completed | 2 | 3 | 2 | 0 | 1 | 1 |
| Not completed | 8 | 9 | 32 | 9 | 8 | 32 |
| Withdrew: Sponsor decision | 0 | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 2 | 1 | 3 | 9 |
| Withdrew: Death | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol specified criteria | 5 | 7 | 27 | 7 | 5 | 21 |
Safety and tolerability were evaluated according to the type, incidence, and severity of adverse events. An AE is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following serious criteria: * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event The severity of each AE was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
| Participants | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Any adverse event (AE) | 10 | 12 | 34 | 9 | 9 | 33 |
| AE Grade ≥ 3 | 7 | 9 | 23 | 5 | 6 | 21 |
| Serious adverse events | 4 | 5 | 10 | 3 | 3 | 11 |
| AEs leading to discontinuation of carfilzomib | 1 | 2 | 5 | 0 | 2 | 1 |
| AEs leading to discontinuation of lenalidomide | 1 | 2 | 5 | 0 | 2 | 2 |
| AEs leading to discontinuation of dexamethasone | 1 | 2 | 5 | 0 | 2 | 2 |
| Fatal adverse events | 0 | 0 | 2 | 0 | 0 | 0 |
| Treatment-related adverse events (TRAE) | 9 | 11 | 30 | 9 | 9 | 32 |
| Treatment-related AEs Grade ≥ 3 | 6 | 8 | 18 | 5 | 5 | 18 |
| Treatment-related serious adverse events | 1 | 2 | 6 | 1 | 3 | 8 |
| TRAEs leading to discontinuation of carfilzomib | 1 | 1 | 5 | 0 | 2 | 1 |
| TRAEs leading to discontinuation of lenalidomide | 1 | 1 | 5 | 0 | 2 | 2 |
| TRAEs leading to discontinuation of dexamethasone | 1 | 1 | 5 | 0 | 2 | 2 |
| Treatment-related fatal adverse events | 0 | 0 | 2 | 0 | 0 | 0 |
| g/L | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Baseline | 116.90 ± 14.58 | 120.67 ± 13.51 | 123.24 ± 16.57 | 111.50 ± 18.04 | 120.00 ± 20.96 | 113.21 ± 16.66 |
| Change from Baseline to Cycle 1 Day 8 | -1.50 ± 7.52 | -3.33 ± 6.39 | -0.91 ± 5.46 | -1.25 ± 8.17 | -5.56 ± 6.11 | -1.82 ± 7.21 |
| Change from Baseline to Cycle 1 Day 15 | -6.90 ± 8.61 | -9.50 ± 6.29 | -5.10 ± 7.88 | -1.75 ± 12.70 | -6.50 ± 10.20 | -5.64 ± 9.10 |
| Change from Baseline to Cycle 2 Day 1 | -5.70 ± 9.78 | -9.25 ± 8.67 | -7.38 ± 7.76 | -3.75 ± 12.65 | -3.29 ± 9.60 | 2.19 ± 10.59 |
| Change from Baseline to Cycle 2 Day 8 | -6.00 ± 11.91 | -8.17 ± 9.00 | -5.59 ± 8.35 | -0.13 ± 14.64 | -2.86 ± 8.49 | 4.19 ± 12.41 |
| Change from Baseline to Cycle 2 Day 15 | -8.50 ± 12.47 | -11.33 ± 8.04 | -8.45 ± 10.08 | 0.00 ± 14.05 | -5.14 ± 13.58 | 2.97 ± 13.04 |
| 10^9 cells/L | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Baseline | 151.60 ± 54.40 | 202.50 ± 67.13 | 172.38 ± 33.70 | 214.00 ± 79.22 | 242.89 ± 99.24 | 233.03 ± 67.76 |
| Change from Baseline to Cycle 1 Day 8 | -12.90 ± 29.88 | -49.50 ± 58.90 | -17.36 ± 21.75 | 2.38 ± 63.66 | -51.11 ± 42.10 | -21.42 ± 36.40 |
| Change from Baseline to Cycle 1 Day 15 | -58.60 ± 32.76 | -66.83 ± 87.14 | -66.39 ± 38.30 | -23.25 ± 116.67 | -101.88 ± 84.66 | -53.39 ± 43.60 |
| Change from Baseline to Cycle 2 Day 1 | 55.00 ± 38.61 | 68.67 ± 84.62 | 44.84 ± 52.82 | 141.75 ± 92.68 | 152.00 ± 244.50 | 111.06 ± 84.26 |
| Change from Baseline to Cycle 2 Day 8 | -44.10 ± 38.14 | -74.75 ± 86.91 | -71.06 ± 37.93 | -28.00 ± 111.10 | -106.29 ± 130.18 | -52.78 ± 60.70 |
| Change from Baseline to Cycle 2 Day 15 | -44.40 ± 21.48 | -63.25 ± 72.53 | -60.13 ± 43.37 | -21.25 ± 82.11 | -76.14 ± 116.02 | -44.19 ± 64.73 |
| 10^9 cells/L | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Baseline | 2.53 ± 1.01 | 3.40 ± 1.54 | 2.72 ± 0.94 | 3.04 ± 0.73 | 3.24 ± 2.24 | 3.26 ± 1.46 |
| Change from Baseline to Cycle 1 Day 8 | 0.02 ± 0.82 | 0.03 ± 1.87 | 0.97 ± 1.19 | 0.59 ± 1.20 | -0.19 ± 1.25 | 0.37 ± 1.29 |
| Change from Baseline to Cycle 1 Day 15 | 0.28 ± 1.14 | -0.09 ± 1.94 | 0.81 ± 1.09 | 1.08 ± 1.53 | 0.43 ± 1.83 | 0.09 ± 1.48 |
| Change from Baseline to Cycle 2 Day 1 | 0.36 ± 1.99 | -0.33 ± 1.59 | 0.16 ± 1.15 | 0.02 ± 0.58 | 0.09 ± 2.46 | 0.18 ± 0.95 |
| Change from Baseline to Cycle 2 Day 8 | 0.18 ± 0.68 | -0.67 ± 1.28 | 0.63 ± 1.08 | 0.57 ± 1.05 | 0.46 ± 2.49 | 0.41 ± 1.25 |
| Change from Baseline to Cycle 2 Day 15 | -0.30 ± 0.71 | -0.54 ± 1.69 | -0.06 ± 1.25 | 0.33 ± 0.53 | 0.56 ± 2.92 | 0.42 ± 2.00 |
| µmol/L | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Baseline | 8.55 ± 3.78 | 9.98 ± 4.72 | 9.10 ± 4.76 | 10.26 ± 4.38 | 6.84 ± 4.01 | 7.16 ± 3.29 |
| Change from Baseline to Cycle 2 Day 1 | 0.86 ± 3.25 | 1.00 ± 3.68 | 1.34 ± 3.52 | 3.42 ± 5.56 | 0.49 ± 2.91 | 1.21 ± 3.10 |
| µmol/L | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Baseline | 80.18 ± 18.57 | 82.88 ± 22.01 | 79.09 ± 17.61 | 75.80 ± 7.78 | 95.37 ± 41.17 | 80.60 ± 21.56 |
| Change from Baseline to Cycle 1 Day 8 | -2.65 ± 5.05 | -5.30 ± 10.29 | 2.09 ± 8.31 | -1.22 ± 8.25 | -8.51 ± 29.44 | -0.22 ± 12.89 |
| Change from Baseline to Cycle 1 Day 15 | -4.42 ± 7.92 | -4.60 ± 11.32 | -1.85 ± 12.69 | 3.65 ± 27.29 | 29.39 ± 130.24 | 0.42 ± 17.59 |
| Change from Baseline to Cycle 2 Day 1 | -3.80 ± 6.81 | -7.74 ± 11.98 | -1.44 ± 9.66 | -10.39 ± 10.05 | -17.17 ± 36.71 | -4.31 ± 9.84 |
| Change from Baseline to Cycle 2 Day 8 | -6.45 ± 4.97 | -11.09 ± 12.70 | 1.85 ± 10.95 | -12.27 ± 8.20 | -20.08 ± 37.86 | -4.32 ± 9.36 |
| Change from Baseline to Cycle 2 Day 15 | -6.28 ± 10.29 | -13.26 ± 9.05 | 4.88 ± 13.78 | -12.38 ± 6.90 | -21.85 ± 39.17 | -1.99 ± 18.08 |
| ng/mL | Carfilzomib 56 mg/m² | Carfilzomib 70 mg/m² |
|---|---|---|
| Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group | 11700 ± 67300 | 12400 ± 45000 |
| hours | Carfilzomib 56 mg/m² | Carfilzomib 70 mg/m² |
|---|---|---|
| Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group | 0.28 (0.17 to 24) | 0.27 (0.17 to 0.68) |
| hr*ng/mL | Carfilzomib 56 mg/m² | Carfilzomib 70 mg/m² |
|---|---|---|
| Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group | 4150 ± 17500 | 9130 ± 32800 |
Response was determined by the investigator based on the International Myeloma Working Group Uniform Response Criteria (IMWG URC). ORR was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Responses must have been confirmed in 2 consecutive assessments at any time prior to initiation of any new therapy. Disease assessments included serum protein electrophoresis (SPEP) with immunofixation, urine protein electrophoresis (UPEP; 24-hour assessment) with immunofixation, serum free light chain (SFLC), quantitative immunoglobulins, bone marrow aspirates to determine percent plasma cell involvement, and skeletal imaging for plasmacytoma evaluation.
| percentage of participants | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | RRMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 90.0 (55.5 to 99.7) | 91.7 (61.5 to 99.8) | 88.2 (72.5 to 96.7) | 89.1 (76.4 to 96.4) | 88.9 (51.8 to 99.7) | 77.8 (40.0 to 97.2) | 83.3 (58.6 to 96.4) | 97.0 (84.2 to 99.9) |
Complete Response Rate (CRR) is defined as the percentage of participants who achieved a best overall response of either stringent complete response (sCR) or complete response (CR) in accordance with International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). sCR: As for CR, and absence of clonal plasma cells in bone marrow (BM) CR: Negative serum and urine immunofixation, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in BM, and normal SFLC ratio in participants with measurable disease only by SFLC.
| percentage of participants | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | RRMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|---|---|
| Complete Response Rate (CRR) | 20.0 (2.5 to 55.6) | 16.7 (2.1 to 48.4) | 26.5 (12.9 to 44.4) | 23.9 (12.6 to 38.8) | 22.2 (2.8 to 60.0) | 11.1 (0.3 to 48.2) | 16.7 (3.6 to 41.4) | 33.3 (18.0 to 51.8) |
PFS is defined as the time from the first day of study treatment to the earlier of disease progression or death due to any cause. Disease progression was determined by the investigator according to IMWG-URC. Progressive Disease (PD): Increase of 25% from lowest value in serum M-component (absolute increase ≥ 0.5 g/dL), urine M-component (absolute increase ≥ 200 mg per 24 hours) and/or the difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, and/or any new or increase in size of bone lesions or soft tissue plasmacytomas, or development of hypercalcemia. PFS was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed assessment visit, were lost to follow-up or withdrew consent were censored at the date of last disease assessment.
| months | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | RRMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | NA (14.8 to NA) | NA (5.6 to NA) | NA (21.1 to NA) | NA (21.1 to NA) | NA (4.7 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Duration of response (DOR) was calculated for participants who achieved a confirmed PR or better based on Investigator assessment and according to the IMWG URC. Duration of overall response is defined as the time from first documentation of response to disease progression or death due to any cause. DOR was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed disease assessment visit, were lost to follow-up, or withdrew consent were censored at the date of last disease assessment.
| months | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | RRMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM: Combined Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) | NA (NA to NA) | NA (11.6 to NA) | NA (20.2 to NA) | NA (20.2 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over All-cause Mortality is reported from the enrollment date up to the end of study; maximum time on study was 30.6 months. Treatment-emergent adverse events are reported from the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RRMM Dose-evaluation: Carfilzomib 56 mg/m² | 0/10 (0%) | 4/10 (40%) | 10/10 (100%) |
| RRMM Dose-evaluation: Carfilzomib 70 mg/m² | 0/12 (0%) | 5/12 (41.7%) | 12/12 (100%) |
| RRMM Dose-expansion: Carfilzomib 70 mg/m² | 2/34 (5.9%) | 10/34 (29.4%) | 33/34 (97.1%) |
| NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| NDMM Dose-expansion: Carfilzomib 70 mg/m² | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| NDMM Dose-expansion: Carfilzomib 56 mg/m² | 0/33 (0%) | 11/33 (33.3%) | 33/33 (100%) |
| Event | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| Thrombotic microangiopathyBlood and lymphatic system disorders | 0/10 | 0/12 | 0/34 | 0/9 | 2/9 | 0/33 |
| Cardiac failure congestiveCardiac disorders | 0/10 | 0/12 | 0/34 | 0/9 | 2/9 | 0/33 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/10 | 2/12 | 0/34 | 0/9 | 0/9 | 0/33 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/10 | 0/12 | 0/34 | 0/9 | 1/9 | 0/33 |
| Angina pectorisCardiac disorders | 0/10 | 0/12 | 0/34 | 1/9 | 0/9 | 0/33 |
| Systemic inflammatory response syndromeGeneral disorders | 0/10 | 0/12 | 0/34 | 1/9 | 0/9 | 0/33 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/10 | 0/12 | 0/34 | 1/9 | 0/9 | 0/33 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/10 | 0/12 | 0/34 | 0/9 | 1/9 | 0/33 |
| Device related infectionInfections and infestations | 1/10 | 0/12 | 0/34 | 0/9 | 0/9 | 0/33 |
| Acute kidney injuryRenal and urinary disorders | 1/10 | 1/12 | 0/34 | 0/9 | 0/9 | 1/33 |
| Event | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/10 | 6/12 | 18/34 | 7/9 | 6/9 | 16/33 |
| FatigueGeneral disorders | 5/10 | 4/12 | 21/34 | 3/9 | 4/9 | 13/33 |
| ConstipationGastrointestinal disorders | 3/10 | 7/12 | 7/34 | 5/9 | 2/9 | 10/33 |
| Upper respiratory tract infectionInfections and infestations | 3/10 | 7/12 | 14/34 | 3/9 | 1/9 | 15/33 |
| HeadacheNervous system disorders | 1/10 | 3/12 | 8/34 | 3/9 | 5/9 | 13/33 |
| NauseaGastrointestinal disorders | 5/10 | 2/12 | 12/34 | 2/9 | 4/9 | 17/33 |
| InsomniaPsychiatric disorders | 4/10 | 3/12 | 7/34 | 2/9 | 0/9 | 17/33 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/10 | 4/12 | 6/34 | 0/9 | 1/9 | 1/33 |
| PyrexiaGeneral disorders | 5/10 | 2/12 | 5/34 | 1/9 | 3/9 | 6/33 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/10 | 6/12 | 10/34 | 2/9 | 3/9 | 8/33 |
All enrolled participants
| Age, Continuous(years) | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² | Total |
|---|---|---|---|---|---|---|---|
| Mean | 67.4 ± 9.3 | 66.4 ± 8.1 | 61.9 ± 11.2 | 59.0 ± 14.0 | 61.8 ± 6.5 | 60.4 ± 10.7 | 61.7 ± 10.6 |
| Age, Customized(Participants) | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² | Total |
|---|---|---|---|---|---|---|---|
| < 65 years | 4 | 5 | 20 | 6 | 6 | 23 | 64 |
| 65 to 74 years | 5 | 6 | 10 | 3 | 3 | 9 | 36 |
| ≥ 75 years | 1 | 1 | 4 | 0 | 0 | 1 | 7 |
| Sex: Female, Male(Participants) | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 5 | 15 | 3 | 3 | 16 | 45 |
| Male | 7 | 7 | 19 | 6 | 6 | 17 | 62 |
| Ethnicity (NIH/OMB)(Participants) | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 3 | 0 | 2 | 1 | 7 |
| Not Hispanic or Latino | 10 | 10 | 30 | 9 | 7 | 30 | 96 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 0 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | RRMM Dose-evaluation: Carfilzomib 56 mg/m² | RRMM Dose-evaluation: Carfilzomib 70 mg/m² | RRMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-evaluation: Carfilzomib 56/70 mg/m² | NDMM Dose-expansion: Carfilzomib 70 mg/m² | NDMM Dose-expansion: Carfilzomib 56 mg/m² | Total |
|---|---|---|---|---|---|---|---|
| Asian | 1 | 1 | 1 | 0 | 0 | 1 | 4 |
| Black or African American | 1 | 4 | 4 | 2 | 1 | 2 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| White | 8 | 7 | 24 | 7 | 7 | 28 | 81 |
| Other | 0 | 0 | 4 | 0 | 1 | 2 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2015 to primary completion in Oct 2019, 53 months.
Results were first posted in Nov 2020, 1 year after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 53 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carfilzomib · Lenalidomide · Dexamethasone